NuCana Announces Pricing of a Public Offering of American Depositary Shares
September 17, 2020 07:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Sept. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer,...
NuCana Announces Proposed Public Offering of American Depositary Shares
September 16, 2020 16:01 ET
|
NuCana plc
EDINBURGH, United Kingdom, Sept. 16, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer,...
NuCana Reports Second Quarter 2020 Financial Results and Provides Business Update
August 19, 2020 16:01 ET
|
NuCana plc
EDINBURGH, United Kingdom, Aug. 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2020 and provided an update on its broad...
NuCana to Present at the 2020 Jefferies Virtual Healthcare Conference
May 27, 2020 07:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, May 27, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...
NuCana Reports First Quarter 2020 Financial Results and Provides Business Update
May 19, 2020 16:01 ET
|
NuCana plc
Clinical Studies Re-Opened to New Patient Enrollment Following Temporary Pause Due to COVID-19 Pandemic Numerous Clinical Data Announcements Expected in 2020 Cash and Cash...
NuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic
May 18, 2020 07:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, May 18, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in multiple clinical studies following the temporary...
NuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020
May 15, 2020 07:00 ET
|
NuCana plc
Non-Clinical Findings Suggest that Acelarin and NUC-3373 May Induce an Immune Response Against Cancer Cells Acelarin (NUC-1031) Releases DAMPs and Upregulates PD-L1 Expression in Lung Cancer Cells ...
NuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121)
May 05, 2020 16:01 ET
|
NuCana plc
EDINBURGH, U.K., May 05, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in NuTide:121, its ongoing global Phase III study of Acelarin...
NuCana Provides Update on Impact of COVID-19 on Clinical Studies
April 02, 2020 16:01 ET
|
NuCana plc
EDINBURGH, United Kingdom, April 02, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) has been closely monitoring the potential impact of the COVID-19 pandemic on its operations and announced...
NuCana Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update
March 10, 2020 16:02 ET
|
NuCana plc
First Patients Dosed in Global Phase III Biliary Tract Cancer Study (NuTide:121) with Potential for Accelerated Approval Filing Numerous Clinical Data Announcements Expected in 2020 Cash and Cash...